All In Biotech

Drug Trial Radar · NCT07900945

Study of Single and Multiple Ascending Doses of CM551 in Healthy Participants

A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Single/Multiple Ascending Doses of CM551 in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
Oct 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-parallel controlled phase I study to evaluate the safety and tolerability of single and multiple doses of CM551 in healthy participants

Conditions

  • Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)

Interventions

  • CM551Biological

    Participants will receive single subcutaneous doses of CM551 solution in a dose escalation format across 4 sequential SAD cohorts.

  • PlaceboDrug

    Participants will receive single subcutaneous doses of CM551-matching placebo solution in a dose escalation format across 4 sequential SAD cohorts.

  • CM551Biological

    Participants will receive repeated subcutaneous doses of CM551 solution in a dose escalation format across 2 sequential MAD cohorts.

  • PlaceboDrug

    Participants will receive repeated subcutaneous doses of CM551-matching placebo solution in a dose escalation format across 2 sequential MAD cohorts.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: through study completion, an average of 1.5 years
  2. Incidence of Treatment-Emergent Adverse EventsTime frame: through study completion, an average of 1.5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.